Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

Original reporting
Published Aug 24, 2026, 10:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 11:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$PMI
Bullish
high confidence
Mentioned
$PMI · $SDOT · $CAPR · $GRI · $BMEA · $YARW
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PMIBullishMed
01

Why it matters

Collective positive catalysts suggest short‑term buying interest across the highlighted names, but each company remains high‑risk.

02

Market read

The article provides fresh, material company‑specific news that can drive short‑term trading decisions in the biotech sector.

03

What to watch

Potential dilution from upcoming financing rounds and execution risk of later‑stage trials.

Relevance 7/10Novelty 7/10Timing: today (2026‑08‑24)

Background

A daily roundup of biotech gainers reporting fresh Q2 results, trial milestones, and regulatory updates.

Company-level read

Ticker impact

$PMIBullishHigh confidence
Context

Q2 2026 revenue rose 39% to $3.0M, net loss narrowed, driving a 40% stock jump.

Expected impact

Further upside if guidance remains strong.

Evidence & confidence

Revenue beat and loss narrowing are material for a small‑cap biotech.

$SDOTBullishMedium confidence
Context

Q2 2026 revenue fell to zero while net income surged to $35.2M, sending shares up 98%.

Expected impact

Volatile upside as market digests the surprise.

Evidence & confidence

Sharp earnings swing creates short‑term trading interest.

$CAPRBullishMedium confidence
Context

FDA extended review of deramiocel BLA to Nov 22, 2026, after submission of extension data, lifting stock 11%.

Expected impact

Potential upside if data remain favorable.

Evidence & confidence

Extension is a material regulatory event for a biotech.

$GRIBullishMedium confidence
Context

Phase 2a data for GRI‑0621 selected for ERS 2026 presentation, boosting shares ~10%.

Expected impact

Likely modest rally ahead of conference.

Evidence & confidence

Conference data selection is a positive catalyst.

$BMEABullishMedium confidence
Context

Completed enrollment in Phase 2 diabetes trial, shares up 14%.

Expected impact

Potential upside as trial progresses.

Evidence & confidence

Enrollment completion is a key development milestone.

$YARWBullishMedium confidence
Context

Phase 2a/2b trial of YB‑101 launched and Fast Track granted, shares up 12%.

Expected impact

Further upside if early data are positive.

Evidence & confidence

Regulatory fast track and trial start are material catalysts.

Market effects

Biotech sector gains momentum as multiple small‑caps report strong trial or regulatory news.

U.S. biotech equities see broad uplift; limited spillover to broader market.

Highlights continued investor appetite for clinical‑stage biotech breakthroughs.

Counterpoint

Rapid price spikes may be over‑optimistic given early‑stage data and small market caps.

Key entities

  • Picard Medical

    Medical device maker reporting Q2 revenue growth.

  • Sadot Group

    Technology firm with net income surge despite zero revenue.

  • Capricor Therapeutics

    Cell‑therapy biotech with FDA review extension.

  • GRI Bio

    IPF drug developer presenting Phase 2a data.

  • Biomea Fusion

    Diabetes trial enrollment completion.

Related articles

$SDOTMed

Sadot Group Reports Third Quarter 2026 Results, Including $69.3 Million Nine-Month Improvement in Shareholders’ Equity and 86% Reduction in Quarterly…

Sadot Group Inc. (SDOT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Sadot Group Reports Third Quarter 2026 Results, Including $69.3 Million Nine-Month Improvement in Shareholders’ Equity and 86% Reduction in Quarterly Operating Loss Company Advances Financial Restructuring, Reports Positive Shareholders’ Equity and Acquires Technolog

$NVDAMed

NVDA Earnings Spark Tech Rally As US Futures Climb — BABA, INTC, ASTS In Focus

Nvidia (NVDA) reported strong Q3 earnings, beating revenue and EPS estimates, driving early premarket gains. Alibaba (BABA) faces scrutiny over ties to a suspected Chinese spy. Intel (INTC) reportedly laid off employees as part of restructuring. Capricor Therapeutics (CAPR) awaits FDA decision on its DMD therapy. AST SpaceMobile (ASTS) faces investor concerns over rocket development. Klarna (KLAR) reported better-than-expected Q3 revenue but missed adjusted EPS estimates.

$NVDAMed

Futures Climb As Nvidia Earnings Boost AI Trade — BABA, INTC, ASTS, CAPR In Focus

Nvidia reported 103% revenue growth to $115.8B, beating estimates. U.S. stock futures rose early Wednesday. Alibaba faces scrutiny over ties to a suspected Chinese spy. Intel confirmed layoffs. Capricor awaits FDA decision on Deramiocel. AST SpaceMobile faces investor concerns over rocket development. Klarna reported Q3 revenue of $1.009B, narrowing losses. Target, Palo Alto Networks, Lowe's, and TJX are set to report earnings.

$SLSMed

‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel

SELLAS Life Sciences (SLS) reported that its REGAL trial of the galinpepimut-S cancer vaccine met the primary overall survival endpoint, with median survival of 24 months vs. 14.7 months for the best available treatment. Shares jumped over 200% on the news. Former pharmaceutical executive Martin Shkreli criticized the data, comparing it to Capricor Therapeutics' (CAPR) Deramiocel data and predicting FDA rejection.